OTC Drug Rules Delayed to March: Presidential Review Pause
Published Date: 1/27/2025
Rule
Summary
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 2 costs, 1 mixed.
Separate NDA/ANDA Required for ACNU Products
The final rule requires applicants seeking approval for a nonprescription drug product with an additional condition for nonprescription use (ACNU) to submit a separate new drug application (NDA) or abbreviated new drug application (ANDA) rather than a supplement when a prescription version is already approved.
New Labeling Content and Format Rules
The final rule establishes specific labeling requirements for nonprescription drug products with an ACNU, including the content and format of specific labeling statements, and it also provides an exemption from the requirement to be labeled with adequate directions for use if certain labeling conditions are met and the ACNU is implemented as approved by FDA.
Postmarketing ACNU Failure Reporting
The final rule requires an applicant to submit a postmarketing report if there is an ACNU failure and states that FDA will refuse to approve an application for a nonprescription drug product with an ACNU if the application fails to meet applicable requirements.
ACNU Can Make OTC Products Marketable
The final rule clarifies that an ACNU constitutes a meaningful difference that can make a nonprescription drug product safe and effective for use without a licensed practitioner; therefore a prescription drug product and a nonprescription drug product with an ACNU and the same active ingredient may be marketed at the same time even if they differ only by the ACNU.
Effective Date Delayed to March 21, 2025
The FDA delayed the final rule "Nonprescription Drug Product With an Additional Condition for Nonprescription Use" from the original effective date of January 27, 2025 to March 21, 2025. Drug makers, sellers, and consumers should note the new start date and use the additional time to plan for the updated application, labeling, and reporting requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2025-01832, Federal Motor Vehicle Safety Standards; Automatic Emergency Braking Systems for Light Vehicles
Starting March 20, 2025, all new light vehicles will need to have automatic emergency braking, pedestrian braking, and forward collision warning systems. This rule update was delayed a bit to review feedback from car makers like Toyota and Volkswagen. If you’re buying or making cars, get ready for safer rides with these smart brakes soon!
Next: C1-2024-30824, Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V)
Starting March 17, 2025, creditors and credit reporting agencies can’t use or share your medical info when deciding on loans or credit. This rule protects your privacy and makes sure your health details don’t mess with your financial life. If you’re applying for credit, expect fairer treatment without medical info bias!